CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer

BACKGROUND: A previous clinical study in non-small cell lung cancer (NSCLC) patients in Western countries suggested the potential for combination of a first-in-class non-ATP-competitive c-Met inhibitor tivantinib with an epidermal growth factor receptor-tyrosine kinase inhibitor erlotinib. Polymorph...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, N, Murakami, H, Hayashi, H, Fujisaka, Y, Hirashima, T, Takeda, K, Satouchi, M, Miyoshi, K, Akinaga, S, Takahashi, T, Nakagawa, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844902/
https://www.ncbi.nlm.nih.gov/pubmed/24169346
http://dx.doi.org/10.1038/bjc.2013.588

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844902/
https://www.ncbi.nlm.nih.gov/pubmed/24169346
http://dx.doi.org/10.1038/bjc.2013.588

Ejemplares similares